An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In VivoHalf-Life

Autor: Xie, Dong, Yao, Cheng, Wang, Li, Min, Wenjie, Xu, Jiahong, Xiao, Jiahai, Huang, Mingxian, Chen, Bo, Liu, Bin, Li, Xiaolin, Jiang, He
Zdroj: Antimicrobial Agents and Chemotherapy; January 2010, Vol. 54 Issue: 1 p191-196, 6p
Abstrakt: ABSTRACTThe clinical application of conventional peptide drugs often is limited by their short in vivohalf-life and potential immunogenicity. Frequent injection presents challenges to the treatment of chronic diseases, such as HIV infection. We chemically modified a peptide HIV fusion inhibitor with 3-maleimidopropionic acid (MPA), which allows rapid and irreversible conjugation with serum albumin at a 1:1 molar ratio. FB006M, with an MPA modification at the 13th amino acid, rapidly formed conjugate with albumin upon intravenous injection, and it exhibited a remarkably extended in vivohalf-life. The albumin conjugate of FB006M displayed potent inhibitory activity against a number of laboratory and clinical isolates of HIV-1 in vitroand in vivo. No immunogenicity or antibody formation was detected after repeated dosing. The clinical application of FB006M may decrease the cost of treatment and improve treatment compliance and patient quality of life.
Databáze: Supplemental Index